Mount Sinai Hospital’s Centre for Inflammatory Bowel Disease
The Centre for Inflammatory Bowel Disease (IBD), one of six centres of excellence at Mount Sinai Hospital, is an international leader in delivering excellence in patient care, education and research for patients with disorders of the gastrointestinal tract (esophagus, stomach, pancreas, liver, small intestine and colon), in particular, Crohn’s disease and ulcerative colitis, the two main forms of IBD.
The Centre brings together Canada’s largest, most comprehensive multidisciplinary team of IBD clinicians including gastroenterologists, colorectal surgeons, nurses, allied health, enterostomal therapists, investigators and research staff. This group of experts works closely with many departments throughout the hospital to deliver in-patient surgical procedures, outpatient clinics, education seminars, training and cutting-edge research breakthroughs.
|The Centre provides both outpatient care and inpatient services, in a uniquely combined medical and surgical IBD unit, to more than 4,700 patients annually, many who come from outside of Toronto and Ontario. The Centre is also the tertiary referral centre for all of Ontario for patients with complex IBD for second opinions and/or ongoing care.|
The Centre’s work is focused on four main areas:
• Inflammatory bowel disease - Crohn’s, Ulcerative Colitis
• Colon cancer screening, prevention and treatment
• General digestive disorders including peptic ulcers and irritable bowel syndrome
• Endoscopy Centre where procedures such as colonoscopies are performed for the purpose of disease diagnosis, early detection and treatment
Setting new standards:
• Mount Sinai’s Dr. Robin McLeod and her team of clinicians from University of Toronto-affiliated hospitals have developed the Best Practice in General Surgery; a standardized program focused evidence-based practices and improved patient care and resident education. The group was recently recognized by the Council of Academic Hospitals of Ontario for their prestigious Adopting Research to Improve Care program for setting a new best practice for improving patient outcomes following colorectal surgery that is now being implemented at 12 hospitals across Ontario.
New surgical procedures:
• The Centre’s surgical program has pioneered a number of surgical techniques that are now used throughout Canada and around the world. Dr. Robin McLeod and Dr. Zane Cohen were among the first surgeons worldwide to perform reconstructive surgery in patients with ulcerative colitis so they do not have to live with a permanent ileostomy. Mount Sinai is now internationally recognized for its expertise in this type of surgery, and patients come from across Canada for surgical care at the Hospital.
New medical therapies:
• The Centre’s gastroenterologists are known for their use of the newest therapies for IBD. Over a decade ago, they were among the first physicians in Canada to offer the new breakthrough biologic drugs to their patients with IBD. They continue to lead the way with the largest experience using this class of drugs in Canada and with innovations in the way the use of the drugs is optimized in individual patients.
|The Zane Cohen Centre for Digestive Diseases is a state-of-the-art facility for both clinical and genetic research and works closely with the Samuel Lunenfeld Research Institute at Mount Sinai. It links a team of gastroenterologists, surgeons, psychiatrists, pathologists and radiologists and their research staff into one common facility who are uncovering new research into areas such as IBD, gastrointestinal cancers and genetic aspects of IBD. This allows for cross-disciplinary research and sharing of core facilities in an environment that fosters collaboration and productivity.|
IBD including Crohn’s disease and ulcerative colitis:
• Mount Sinai’s Drs. Kenneth Croitoru and Hillary Steinhart, with financial support from the Crohn’s and Colitis Foundation of Canada, are leading the GEM study, the world’s first large-scale study designed to try to identify the cause of Crohn’s disease by studying individuals who are presently healthy but are at increased risk of developing the disease, by virtue of their family history.
• Mount Sinai’s Drs. Mark Silverberg and Hillary Steinhart are part of an international consortium of researchers who discovered twenty-one new genetic risk factors associated with Crohn’s disease.
• Mount Sinai’s Dr. Steven Gallinger identified a gene associated with colorectal cancer – the first clue for future screening methods.
• Dr. Steven Gallinger is helping to lead the Ontario Pancreas Cancer Study, an ongoing registry that examines factors associated with pancreas cancer, such as genetics and lifestyle, as well as what treatments are available to patients with the disease.
• Dr. Robert Gryfe is focused on the genetics of colorectal cancer, prognosis, and response to treatment.
Genetic aspects of IBD:
• Dr. Mark Silverberg is involved in research focused on personalized medicine – where a patient’s unique genetic signature can help to predict the severity of disease and the response to treatment, potentially mitigating the complications of severe disease.
• In 2009, Mount Sinai investigators led by Dr. Mark Silverberg discovered five new regions in the genome associated with susceptibility to IBD in children and youth that could lead to new therapies.
• The GEM and genetic studies have led to Mount Sinai’s efforts to establish a genetic counseling program for IBD patients and their families, which is available to individuals from across Canada and is the first of its kind in the world.
|The Centre has advanced training programs in gastroenterology and colorectal surgery for local, national and international physicians who are completing their clinical training and want additional expertise in the management of digestive diseases and maintaining digestive health.|
Located at Mount Sinai, the Rachel M. Flood Ostomy and Wound Education Centre, is focused on being a regional, national and international centre of excellence in education, clinical skill development and research in ostomy and wound management. As the first program of its kind in Canada, it enables health-care professionals to provide best practices to improve care for patients and families as well as provide advanced knowledge and training in the management of digestive health.
Leading the way in treating patients with Inflammatory Bowel Disease http://www.mountsinai.on.ca/about_us/news/2012-news/leading-the-way-in-treating-patients-with-inflammatory-bowel-disease/